Critical limb ischemia

被引：10

作者：

Dawson D.L. ^{[1
]}

Mills Sr. J.L. ^{[1
]}

机构：

[1] UC Davis Vascular Center, Sacramento, CA 95817

来源：

Current Treatment Options in Cardiovascular Medicine | 2007年 / 9卷 / 2期

关键词：

Peripheral Artery Disease; Limb Salvage; Superficial Femoral Artery; Critical Limb Ischemia; Endovascular Therapy;

D O I：

10.1007/s11936-007-0009-2

中图分类号：

学科分类号：

摘要：

Critical limb ischemia (CLI) is the most severe manifestation of peripheral artery disease (PAD). Without timely recognition, appropriate diagnosis, and revascularization, patients with CLI are at risk for amputation or potentially fatal complications. The past decade has seen substantial growth in endovascular CLI therapies and options now exist for treating long-segment lower-extremity arterial occlusive disease, but surgical bypass may yield more durable results. Patients who are younger, more active, and at low risk for surgery may have better outcomes with an operation. Surgical treatment is also indicated for failures of endovascular therapy, which may include early technical failures or later occlusion after placement of stents or other interventions. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：159 / 170

页数：11

共 55 条

[1]

Hemodynamics for Surgeons, pp. 278-281, (1975)

[2]

Dormandy J.A., Rutherford R.B., Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC), J Vasc Surg, 31, 1 PART 2, (2000)

[3]

Leville C.D., Kashyap V.S., Clair D.G., Et al., Endovascular management of iliac artery occlusions: Extending treatment to TransAtlantic Inter-Society Consensus class C and D patients, J Vasc Surg, 43, pp. 32-39, (2006)

[4]

Balzer J.O., Gastinger V., Ritter R., Et al., Percutaneous interventional reconstruction of the iliac arteries: Primary and long-term success rate in selected TASC C and D lesions, Eur Radiol, 16, pp. 124-131, (2006)

[5]

Adam D.J., Beard J.D., Cleveland T., Et al., Bypass versus angioplasty in severe ischaemia of the leg (BASIL): Multicentre, randomised controlled trial, Lancet, 366, pp. 1925-1934, (2005)

[6]

Dawson D.L., Hiatt W.R., Creager M.A., Hirsch A.T., Peripheral arterial disease: Medical care and prevention of complications, Prev Cardiol, 5, pp. 119-130, (2002)

[7]

Conte M.S., Bandyk D.F., Clowes A.W., Et al., Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery, J Vasc Surg, 43, pp. 742-751, (2006)

[8]

Hankey G.J., Norman P.E., Eikelboom J.W., Medical treatment of peripheral arterial disease, JAMA, 295, pp. 547-553, (2006)

[9]

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report [no authors listed], Circulation, 106, pp. 3143-3421, (2002)

[10]

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [no authors listed], BMJ, 324, pp. 71-86, (2002)

← 1 2 3 4 5 6 →